Our aim is to link non-invasive imaging and nucleic acid biotechnology to create new in vivo imaging methods. Oligonucleotide ligands termed aptamers bind with high affinity biological targets and can be obtained from large combinatorial libraries. Modified aptamers engineered to resist degradation and target molecular markers of disease are thus promising candidates both as diagnostic tools and as therapeutic agents. Using non-invasive imaging procedures (PET) , we will evaluate in animal models of disease the potential of stable aptamers for diagnostic and therapy. This project merges 6 groups specialized in the following fields:
i) biologically-stable aptamer production (including a leading biotech company);
ii) study of biomarkers in animal disease models, and
iii) in vivo imaging methods. The major spin-off expected is the creation of generic methods for diagnosis and evaluation of new therapies.
Funding SchemeCSC - Cost-sharing contracts
91198 Gif Sur Yvette
10126 Torino (Turin)